We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
-3.4%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$18.2B
AUM Growth
-$235M
Cap. Flow
-$283M
Cap. Flow %
-1.55%
Top 10 Hldgs %
32.02%
Holding
333
New
17
Increased
37
Reduced
36
Closed
22

Top Buys

Rank Stock Value
1
ZEN
ZENDESK INC
ZEN
+$262M
2
CLVT icon
Clarivate
CLVT
+$202M
3
CHNG
Change Healthcare Inc. Common Stock
CHNG
+$196M
4
SPGI icon
S&P Global
SPGI
+$139M
5
HUM icon
Humana
HUM
+$122M

Top Sells

Rank Stock Value
1
COHR
Coherent Inc
COHR
+$154M
2
HWM icon
Howmet Aerospace
HWM
+$140M
3
CSGP icon
CoStar Group
CSGP
+$139M
4
BSX icon
Boston Scientific
BSX
+$116M
5
MANT
Mantech International Corp
MANT
+$92.7M

Sector Composition

Rank Sector Weight
1 Healthcare 28.39%
2 Technology 19.07%
3 Financials 13.73%
4 Industrials 8.28%
5 Communication Services 8.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FRSGW
276
DELISTED
First Reserve Sustainable Growth Corp. Warrant
FRSGW
$7K ﹤0.01%
100,000
– –
RKTA.WS
277
DELISTED
Rocket Internet Growth Opportunities Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
RKTA.WS
$7K ﹤0.01%
125,000
– –
DAOOW
278
DELISTED
Crypto 1 Acquisition Corp Warrants
DAOOW
$7K ﹤0.01%
75,000
– –
RGTIW icon
279
Rigetti Computing Warrants
RGTIW
$178M
$6K ﹤0.01%
23,475
– –
SCOBW
280
DELISTED
ScION Tech Growth II Warrants
SCOBW
$6K ﹤0.01%
150,000
– –
GETR.WS
281
DELISTED
Getaround, Inc. Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share
GETR.WS
$5K ﹤0.01%
80,000
– –
AEON.WS
282
DELISTED
AEON Biopharma Inc
AEON.WS
$4K ﹤0.01%
49,995
– –
FSRXW
283
DELISTED
FinServ Acquisition Corp. II Warrant
FSRXW
$4K ﹤0.01%
150,000
– –
ANAC.WS
284
DELISTED
Arctos NorthStar Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
ANAC.WS
$4K ﹤0.01%
50,000
– –
HIIIW
285
DELISTED
Hudson Executive Investment Corp. III Warrant
HIIIW
$4K ﹤0.01%
50,000
– –
LGV.WS
286
DELISTED
Longview Acquisition Corp. II Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock, each at an exercise price of $11.50 per share
LGV.WS
$4K ﹤0.01%
60,940
– –
MVLAW
287
DELISTED
Movella Holdings Inc. Warrant
MVLAW
$3K ﹤0.01%
150,000
– –
LGACW
288
DELISTED
Lazard Growth Acquisition Corp. I Warrants
LGACW
$3K ﹤0.01%
60,000
– –
RXRAW
289
DELISTED
RXR Acquisition Corp. Warrants to purchase Class A common stock
RXRAW
$3K ﹤0.01%
120,000
– –
TMAC.WS
290
DELISTED
The Music Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
TMAC.WS
$2K ﹤0.01%
62,500
– –
SLAMW
291
DELISTED
Slam Corp. warrant
SLAMW
$1K ﹤0.01%
17,627
– –
NSTD.WS
292
DELISTED
Northern Star Investment Corp. IV Redeemable Warrants, each whole warrant exercisable for shares of Class A common stock at an exercise price of $11.50 per share
NSTD.WS
$1K ﹤0.01%
16,666
– –
LDHAW
293
DELISTED
LDH Growth Corp I Warrant
LDHAW
$1K ﹤0.01%
30,000
– –
NSTC.WS
294
DELISTED
Northern Star Investment Corp. III Redeemable Warrants, each whole warrant exercisable for shares of Class A common stock at an exercise price of $11.50 per share
NSTC.WS
$1K ﹤0.01%
16,667
– –
ANNX icon
295
Annexon
ANNX
$961M
– –
-130,000
Closed -$490K
BPMC
296
DELISTED
Blueprint Medicines
BPMC
– –
-1,211,987
Closed -$61.2M
HR icon
297
Healthcare Realty
HR
$6.65B
– –
-500,000
Closed -$14M
IMA
298
ImageneBio Inc
IMA
$62.5M
– –
-24,167
Closed -$1.28M
IOVA icon
299
Iovance Biotherapeutics
IOVA
$3.76B
– –
-3,176,773
Closed -$35.1M
NVAX icon
300
Novavax
NVAX
$1.47B
– –
-498,000
Closed -$25.6M
9 10 11
12
13

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2022 Portfolio in Review

As of Q3 2022, Thomas Steyer held 333 positions worth $18.2B, down 1.3% from $18.4B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Thomas Steyer's Q3 2022 filing shows 17 new, 37 increased, 36 reduced and 22 closed positions. Its largest new stake was Humana: 251,200 shares worth $122M. The largest sale was Coherent Inc, an estimated $154M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, down from 31% a quarter earlier, followed by Technology and Financials.

  • Thomas Steyer's largest Q3 2022 buy was Humana: 251,200 shares worth $122M.
  • Thomas Steyer added most to ZENDESK INC in Q3 2022, an estimated $262M increase.
  • Thomas Steyer's biggest Q3 2022 reduction was Howmet Aerospace, cutting an estimated $140M.
  • Thomas Steyer fully exited Coherent Inc in Q3 2022, selling an estimated $154M.
  • Thomas Steyer's ten largest holdings make up 32% of its $18.2B portfolio in Q3 2022.
  • Thomas Steyer opened 17 new positions and closed 22 in Q3 2022.
  • Thomas Steyer's portfolio value fell 1.3% quarter-over-quarter to $18.2B.

Based on Farallon Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.